Chronic Inflammatory Demyelinating Polyneuropathy

Authors

Keywords:

typical chronic demyelinating inflammatory polyneuropathy; symmetrical muscle weakness; osteotendinous areflexia; immunomodulatory treatment.

Abstract

Introduction: Chronic inflammatory demyelinating polyneuropathy is, within the inflammatory neuropathies, the most common acquired and chronic demyelinating and immune-mediated form.

Objective: To report two clinical cases of chronic inflammatory demyelinating polyneuropathy.

Case report: Two clinical cases over 13 years of age, male adolescents, with nadir from the onset of symptoms between ten and three months. Personal history of immunological diseases and IgA deficiency in childhood, and type 1 diabetes mellitus, respectively; no significant family history or history of previous infections, toxic habits, and poisoning. Both presented with symmetrical weakness of the upper and lower limbs to lower predominance, difficulty walking and during exercise, nocturnal pain, paresthesias, osteotendinous areflexia and signs of anxiety, insomnia; and one case with one suicide attempt related to his symptoms. First case with thenar, hypothenar and tarzal atrophy, cavus feet and stepagge gait tendency. Both cases showed albuminocytological dissociation in cerebrospinal fluid, neuroconduction study with decreased conduction velocity in motor and sensory nerves with motor predominance and a favorable response to immunomodulatory treatment.

Conclusions: The two reported cases exhibited clinical characteristics of typical chronic inflammatory demyelinating polyneuropathy —predominantly motor— with differing nadirs at onset and distinct comorbidities, and demonstrated a favorable response to immunomodulatory treatment with first-line medications.

Downloads

Download data is not yet available.

References

1. Querol L, Lleixa C. Novel Immunological and Therapeutic Insights in Guillain‑Barre Syndrome and CIDP. Neurotherapeutics. 2021;18:2222-35. DOI: https://doi.org/10.1007/s13311-021-01117-3

2. Vidal H, Mesa C, Benitez J, Jorquera J. Polineuropatía desmielinizante inflamatoria crónica: revisión a propósito de un caso. Rev Chil Neuro-Psiquiat. 2019 [acceso 30/01/2025];57(3):283-94. Disponible en: https://www.scielo.cl/pdf/rchnp/v57n3/0717-9227-rchnp-57-03-0283.pdf

3. Phillips Morales O. Actualización en el Síndrome de Guillain-Barre. Rev Med Sinergia. 2019;4(11):290-300. DOI: https://doi.org/10.31434/rms. v4i11.290

4. Meireles ALF. Polineuropatia desmielinizante inflamatória crônica – uma revisão narrativa / Chronic inflammatory demyelinating polyradiculoneuropathy – a narrative review. Rev Med (São Paulo). 2021;100(1):57-61. DOI: https://doi.org/10.11606/issn.1679-9836.v100i1p57-61

5. Brun S, de Sèze J, Muller S. CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention. Immunol. 2022;2:118-31. DOI: https://doi.org/10.3390/immuno201000

6. Ricciardi D, Amitrano F, Coccia A, Todisco V, Trojsi F, Tedeschi G, et al. Neurophysiological Hallmarks of Axonal Degeneration in CIDP Patients: A Pilot Analysis. Brain Sci. 2022;12:1510-22. DOI: https://doi.org/10.3390/brainsci12111510

7. Gitiaux C. Polirradiculoneuritis adquiridas agudas y crónicas en la infancia. EMC-Pediatría. Neurol. 2024 [acceso 26/01/2025];59(1):1-8. Disponible en: https://www.sciencedirect.com/science/article/pii/S1245178923487756

8. Llauradó A, Sánchez-Tejerina D, Vidal-Taboada JM, Salvado M, Sotoca J, Juntas-Morales R. Biomarcadores pronósticos y de seguimiento en la polineuropatía desmielinizante inflamatoria crónica. Rev Neurol. 2022;74:232-41. DOI: https://doi.org/10.33588/rn.7407.2021495

9. Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021 [acceso 26/01/2025];26:242-68. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34327760/

10. Escamilla-Ramírez A, López-Hernández JC, Díaz-Martínez R, Galnares-Olalde J, Vargas-Cañas ES. Patrones clínicos y neurofisiológicos de presentación temprana en la polirradiculoneuropatía inflamatoria desmielinizante crónica de inicio agudo. Rev Neurol. 2022 [acceso 26/01/2025];75:341-7. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280742/

11. Shastri A, Al Aiyan A, Kishore U, Farrugia ME. Immune-Mediated Neuropathies: Pathophysiology and Management. Int J Mol Sci. 2023;24:7288-317. DOI: https://doi.org/10.3390/ijms24087288

12. Sheikh KA. Guillain-Barré Syndrome. Continuum (Minneap Minn). 2020 [acceso 25/01/2025];26(5):1184-204. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33002998/

13. Broers MC, de Wilde M, Lingsma HF, van der Lei J, Verhamme KMC, Jacobs BC. Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands. J Peripher Nerv Syst. 2022;27(3):182-8. DOI: https://doi.org/10.1111/jns.12502

14. Łukawska M, Potulska-Chromik A, Lipowska M, Hoffman-Zacharska D, Olchowik B, Figlerowicz M, et al. Pediatric CIDP: Diagnosis and Management. A Single-Center Experience. Front Neurol. 2021;12:667378. DOI: https://doi.org/10.3389/fneur.2021.667378

15. Silva ACB, Corrêa LB, Ribeiro DCSRA, Felício I, Vasconcelos MM. Polineuropatia desmielinizante inflamatória crônica na infância. Rev Pediatr SOPERJ. 2016 [acceso 20/01/2025];16(3):45-8. Disponible en: http://revistadepediatriasoperj.org.br/detalhe_artigo.asp?id=801

Downloads

Published

2026-03-29

How to Cite

1.
Portuondo Barbarrosa E, Gutiérrez Gil JV, Santiesteban Velázquez N de J. Chronic Inflammatory Demyelinating Polyneuropathy. Rev Cubana Pediatría [Internet]. 2026 Mar. 29 [cited 2026 Apr. 1];98:e7902. Available from: https://revpediatria.sld.cu/index.php/ped/article/view/7902

Issue

Vol. 98 (2026): publicación continua

Section

PEDIATRÍA

License

Copyright (c) 2026 Ernesto Portuondo Barbarrosa, Jose Victor Gutíerrez Gil, Norge de Jesús Santiesteban Velázquez

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Avisos de derechos de autor propuestos por Creative Commons

1. Política propuesta para revistas que ofrecen acceso abierto

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:

  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).